Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads

被引:91
作者
Wein, LM [1 ]
D'Amato, RM
Perelson, AS
机构
[1] MIT, Sloan Sch Management, Cambridge, MA 02139 USA
[2] MIT, Ctr Operat Res, Cambridge, MA 02139 USA
[3] Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA
关键词
D O I
10.1006/jtbi.1997.0622
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Motivated by the ability of combinations of antiretroviral agents to sustain viral suppression in HIV-1-infected individuals, we analyse the transient and steady-state behavior of a mathematical model of HIV-1 dynamics in vivo in order to predict whether these drug regimens can eradicate HIV-1 or maintain viral loads at low levels. The model incorporates two cell types (CD4(+) T cells and a long-lived pool of cells), two strains of virus (drug-sensitive wild type and drug-resistant mutant) and two types of antiretroviral agents (reverse transcriptase and protease inhibitors). The transient behavior of the cells and virus and the eventual eradication of the virus are determined primarily by the strength of the combination therapy against the mutant strain and the maximum achievable increase in the uninfected CD4(+) T cell concentration. We also predict, if the parameters of the model remain constant during therapy, that less intensive maintenance regimens will be unable to maintain low viral loads for extensive periods of time. However, if the reduction in viral load produced by therapy reduces the state of activation of the immune system, the number of cells susceptible for HIV-1 infection may decrease even though total CD4(+) T cells increase. Our model predicts that if this occurs strong inductive therapy that reduces viral load followed by weaker maintenance regimes may succeed.
引用
收藏
页码:81 / 98
页数:18
相关论文
共 73 条
[11]  
DEBOER RJ, 1997, IN PRESS J THEORET B
[12]   Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine [J].
deJong, MD ;
Veenstra, J ;
Stilianakis, NI ;
Schuurman, R ;
Lange, JMA ;
deBoer, RJ ;
Boucher, CAB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (11) :5501-5506
[13]   ANALYSIS OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTED TISSUES BY AMPLIFICATION AND INSITU HYBRIDIZATION REVEALS LATENT AND PERMISSIVE INFECTIONS AT SINGLE-CELL RESOLUTION [J].
EMBRETSON, J ;
ZUPANCIC, M ;
BENEKE, J ;
TILL, M ;
WOLINSKY, S ;
RIBAS, JL ;
BURKE, A ;
HAASE, AT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (01) :357-361
[14]   TREATMENT WITH LAMIVUDINE, ZIDOVUDINE, OR BOTH IN HIV-POSITIVE PATIENTS WITH 200 TO 500 CD4+ CELLS PER CUBIC MILLIMETER [J].
ERON, JJ ;
BENOIT, SL ;
JEMSEK, J ;
MACARTHUR, RD ;
SANTANA, J ;
QUINN, JB ;
KURITZKES, DR ;
FALLON, MA ;
RUBIN, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1662-1669
[15]  
ESSUNGER P, 1997, INT WORKSH HIV DRUG
[16]   Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy [J].
Finzi, D ;
Hermankova, M ;
Pierson, T ;
Carruth, LM ;
Buck, C ;
Chaisson, RE ;
Quinn, TC ;
Chadwick, K ;
Margolick, J ;
Brookmeyer, R ;
Gallant, J ;
Markowitz, M ;
Ho, DD ;
Richman, DD ;
Siliciano, RF .
SCIENCE, 1997, 278 (5341) :1295-1300
[17]   QUASI-SPECIES DYNAMICS AND THE EMERGENCE OF DRUG-RESISTANCE DURING ZIDOVUDINE THERAPY OF HIV-INFECTION [J].
FROST, SDW ;
MCLEAN, AR .
AIDS, 1994, 8 (03) :323-332
[18]  
Furth R., 1992, INFLAMMATION BASIC P, P325
[19]   THE ROLE OF MONONUCLEAR PHAGOCYTES IN HTLV-III LAV INFECTION [J].
GARTNER, S ;
MARKOVITS, P ;
MARKOVITZ, DM ;
KAPLAN, MH ;
GALLO, RC ;
POPOVIC, M .
SCIENCE, 1986, 233 (4760) :215-219
[20]  
Goletti D, 1996, J IMMUNOL, V157, P1271